DCT

1:24-cv-01014

Novo Nordisk Inc v. Sun Pharmaceutical Industries Ltd

Log In

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:24-cv-01014, D. Del., 09/05/2024
  • Venue Allegations: Venue is alleged to be proper as Defendant Sun Pharmaceutical Industries, Inc. is a Delaware corporation that resides in the district, and Defendant Sun Pharmaceutical Industries Ltd. is a foreign corporation. The complaint also asserts personal jurisdiction based on prior business conduct and litigation within the district.
  • Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's Wegovy® (semaglutide) injection constitutes an act of infringement of a patent covering methods of using semaglutide for weight reduction.
  • Technical Context: The technology concerns specific dosage regimens for semaglutide, a GLP-1 receptor agonist, a class of drugs that has become a cornerstone of the rapidly growing market for pharmaceutical weight management therapies.
  • Key Procedural History: This action was filed under the Hatch-Waxman Act framework following Defendant's submission of an ANDA seeking FDA approval. The patent-in-suit is listed in the FDA's "Orange Book" for Wegovy®. The complaint notes several prior patent litigations in the District of Delaware involving the same parties on other matters, which Plaintiff cites to support personal jurisdiction.

Case Timeline

Date Event
2017-10-12 U.S. Patent No. 12,029,779 Priority Date
2024-07-09 U.S. Patent No. 12,029,779 Issue Date
2024-09-05 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,029,779 - "Semaglutide in Medical Therapy"

  • Patent Identification: U.S. Patent No. 12,029,779, "Semaglutide in Medical Therapy," issued July 9, 2024.

The Invention Explained

  • Problem Addressed: The patent background identifies that while GLP-1 receptor agonists like liraglutide are used for weight management, their use is often associated with gastrointestinal side effects, particularly nausea, and that "improved medical therapies for weight management are still desired" (’779 Patent, col. 1:16-27).
  • The Patented Solution: The patent describes the "surprising" discovery that administering semaglutide at high dosages, such as 2.0-4.0 mg once weekly, results in improved weight loss with a favorable safety profile (’779 Patent, col. 2:41-48). The core of the invention is a method that provides a beneficial ratio between the desired effect (body weight reduction) and undesired side effects (gastrointestinal events), allowing for more effective weight management than previously achieved (’779 Patent, col. 2:50-58).
  • Technical Importance: The invention claims a specific method of use for semaglutide that enables significant weight loss at a high dose while maintaining a manageable side effect profile, addressing a key clinical challenge in obesity treatment (’779 Patent, col. 2:25-30).

Key Claims at a Glance

  • The complaint asserts infringement of claims 2 and 7, which depend on or are related to independent claims 1 and 7 (’779 Patent, col. 10:43-52, col. 10:60-63).
  • Independent Claim 1:
    • A method for reducing body weight of a subject in need thereof,
    • comprising administering semaglutide subcutaneously to the subject,
    • in an amount of about 2.4 mg weekly.
  • Independent Claim 7:
    • A method for reducing body weight of a subject in need thereof,
    • comprising administering semaglutide subcutaneously to the subject,
    • in an amount of 2.4 mg once weekly.
  • The complaint reserves the right to assert additional claims (Compl. ¶22).

III. The Accused Instrumentality

Product Identification

  • Defendant’s ANDA No. 217962 seeks approval for a generic version of semaglutide injection, referred to as "Sun's ANDA Product" (Compl. ¶7, ¶18). The application covers multiple strengths, including 2.4 mg/0.75 mL single-dose pens for subcutaneous use (Compl. ¶18).

Functionality and Market Context

  • The accused product is a generic version of Novo Nordisk's Wegovy® and is alleged to be bioequivalent (Compl. ¶21). The active ingredient is semaglutide, the structure of which is depicted in the complaint's Figure 1 (Compl. ¶15). The complaint alleges that Sun's proposed label will, as required by FDA regulations, essentially copy the Wegovy® label, which instructs a once-weekly subcutaneous injection for weight reduction, with a recommended maintenance dosage of 2.4 mg (Compl. ¶13, ¶40, ¶44). This visual, "Figure 1. Structural Formula of semaglutide," confirms the chemical identity of the active ingredient at issue (Compl. ¶15).

IV. Analysis of Infringement Allegations

’779 Patent Infringement Allegations (Claim 1)

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for reducing body weight of a subject in need thereof The proposed label for Sun's ANDA Product will allegedly mirror the Wegovy® label, which indicates the drug is for reducing excess body weight in adults and pediatric patients with obesity or overweight (Compl. ¶11). ¶11, ¶36, ¶44 col. 10:43-44
comprising administering semaglutide The active ingredient in the accused ANDA product is semaglutide (Compl. ¶15, ¶18). ¶15, ¶18, ¶37 col. 10:44-45
subcutaneously to the subject The Wegovy® label, which Sun's label allegedly copies, instructs administration by subcutaneous injection (Compl. ¶12, ¶40). ¶12, ¶40, ¶44 col. 10:45
in an amount of about 2.4 mg weekly The Wegovy® label, which Sun's label allegedly copies, instructs a recommended maintenance dosage of 2.4 mg once weekly (Compl. ¶13, ¶38). Sun’s ANDA seeks approval for a 2.4 mg dosage strength (Compl. ¶18). ¶13, ¶18, ¶38 col. 10:46

’779 Patent Infringement Allegations (Claim 7)

Claim Element (from Independent Claim 7) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for reducing body weight of a subject in need thereof The proposed label for Sun's ANDA Product will allegedly mirror the Wegovy® label, which indicates the drug is for reducing excess body weight in adults and pediatric patients with obesity or overweight (Compl. ¶11). ¶11, ¶36, ¶44 col. 10:60-61
comprising administering semaglutide subcutaneously to the subject The active ingredient is semaglutide, administered via subcutaneous injection as per the allegedly copied Wegovy® label (Compl. ¶12, ¶15, ¶18, ¶40). ¶12, ¶15, ¶40 col. 10:61-62
in an amount of 2.4 mg once weekly The Wegovy® label, which Sun's label allegedly copies, instructs a recommended maintenance dosage of 2.4 mg once weekly (Compl. ¶13, ¶38). Sun’s ANDA seeks approval for a 2.4 mg dosage strength (Compl. ¶18). ¶13, ¶18, ¶38 col. 10:63

Identified Points of Contention

  • Scope Questions: The primary dispute may center on the scope of the dosage limitations. A key question for the court will be the interpretation of "about 2.4 mg" in claim 1, and how its scope compares to the precise "2.4 mg" limitation in claim 7. The doctrine of claim differentiation may be invoked to argue that "about 2.4 mg" must encompass a range broader than the exact value recited in claim 7.
  • Technical Questions: As this is an ANDA case based on a future product, the central evidentiary question will be whether the instructions on Sun’s proposed product label will necessarily lead a user to perform each step of the claimed method. The complaint's theory rests on the allegation that FDA regulations require Sun’s label to be substantially the same as the Wegovy® label for the relevant indications (Compl. ¶44).

V. Key Claim Terms for Construction

Key Term: "about 2.4 mg" (Claim 1)

  • Context and Importance: The construction of "about" will define the literal scope of the dosage limitation in claim 1. Practitioners may focus on this term because its breadth is central to the infringement analysis; a narrow interpretation could potentially allow a generic competitor to design around the claim, whereas a broad interpretation would make infringement more likely for any product dosed near 2.4 mg.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification discloses weekly dosages in ranges, such as "2.0-4.0 mg once weekly" and "about 2.2 mg, about 2.3 mg, or about 2.4 mg" (’779 Patent, col. 2:19-20, col. 3:20-22). This use of ranges and the explicit use of "about" suggest the patentee did not intend to limit the invention to a precise numerical value.
    • Evidence for a Narrower Interpretation: A party could argue that the meaning of "about" should be constrained by the context of the clinical trial data discussed in the patent, which tested specific daily doses (’779 Patent, col. 8, Table 1). Furthermore, the presence of claim 7, which recites "2.4 mg" without "about," could be used to argue under the doctrine of claim differentiation that "about 2.4 mg" must mean something other than exactly 2.4 mg, or that the patentee knew how to be precise when it was intended.

VI. Other Allegations

Indirect Infringement

  • The complaint alleges that Sun will induce infringement under 35 U.S.C. § 271(b) (Compl. ¶23). The factual basis for this claim is the allegation that Sun's proposed product label, by essentially copying the FDA-approved Wegovy® label, will instruct and encourage physicians and patients to administer the generic product according to the patented method (Compl. ¶44). The complaint also asserts that Wegovy® has no substantial non-infringing uses, supporting a claim for contributory infringement (Compl. ¶46).

Willful Infringement

  • The complaint alleges that "Sun has actual knowledge of the '779 Patent" (Compl. ¶35) and seeks enhanced damages and attorneys' fees, suggesting an allegation of willful infringement and/or that the case is exceptional (Compl. ¶54, ¶55). The basis for knowledge appears to be, at a minimum, post-suit, given the patent's recent issuance.

VII. Analyst’s Conclusion: Key Questions for the Case

  • A core issue will be one of claim construction: How will the court define the scope of the dosage limitation "about 2.4 mg" in claim 1, particularly in light of claim 7's precise recitation of "2.4 mg"? The outcome of this question will be critical to the infringement analysis for Sun's 2.4 mg proposed product.
  • A central question of inducement will be whether the contents of Sun's to-be-approved product label constitute sufficient evidence of a specific intent to encourage infringement. The analysis will likely focus on whether the label directs users to perform the patented method for its stated purpose of weight reduction, as opposed to achieving weight loss as an unintended side effect of another treatment.